November 7, 2005

Pfizer's Vfend equals two-drug candidema regimen, with fewer serious side effects, Lancet study

"This study proves the effectiveness of Vfend for the treatment of candidemia, an often-deadly fungal infection for which we need multiple treatment options," said Dr. Jack D. Sobel, study investigator and professor and chief of the Division of Infectious Diseases at Wayne State University .

Subscribe to Today@Wayne

Direct to your inbox each week

Related articles